How to Appeal a Step Therapy Denial
What is a step therapy denial?
Step therapy, sometimes called fail first, means the plan will not cover a drug until you try a different drug it prefers. You can ask the plan to waive that requirement or appeal the denial. Medicare Part D and Medicare Advantage Part B drugs follow specific federal clocks. A plan that provides essential health benefits has a separate process for a drug it does not cover. Many states have their own step-therapy laws for some insured plans. This page does not list those state rules, and it does not promise that the plan will approve the drug.
Get help with my bill →What the denial is saying
The points below were checked on CMS, eCFR, HealthCare.gov, and Medicare.gov on November 14, 2026.
Read the notice for the drug name, the strength, and the reason. Step therapy is one limit. A denial can instead say the drug is not on the formulary, needs prior authorization, exceeds a quantity limit, or is not medically necessary. Those are not the same request. A specialty-drug denial that may be any of those is in a specialty medication denied by insurance. A prior-authorization denial is in a prior authorization denial.
Ask the prescriber which drugs the plan wants tried, whether you have already tried them, and whether trying them would be unsafe or unlikely to work. Do not change or stop a medicine on your own. Ask the prescriber what to do if you may run out while the request is pending. If the drug is not on the formulary at all, rather than covered only after another drug, see a prescription drug the plan will not cover. If the drug was prescribed for weight loss, see a weight-loss medication denial. Birth control has its own preventive rule, including when a plan wants a different method first. See birth control that was billed. If the denial is for step therapy before Botox for chronic migraine, see a Botox denial for migraines.
How do I ask a Medicare Part D plan to waive step therapy?
CMS says an exception is a coverage determination. You, your prescriber, or your representative may request one. A formulary exception includes a request to waive a utilization-management rule, and CMS names step therapy, prior authorization, and a quantity limit as examples. The prescriber must send a supporting statement. For a step-therapy waiver, CMS says that statement must indicate that the alternative required by step therapy has been, or is likely to be, less effective or to have adverse effects. The prescriber may send the statement verbally or in writing. If it is verbal, the plan may require a written follow-up. 42 CFR 423.578 is the exceptions process.
CMS says that once the plan has the prescriber's supporting statement, it must provide notice of its decision within 24 hours for an expedited request or 72 hours for a standard request. The first notice may be verbal if a written notice is mailed within 3 calendar days. A request for payment, rather than for the drug itself, that involves an exception must be decided within 14 calendar days after the plan receives the request. If the decision is unfavorable, CMS says the notice contains the information needed to ask the plan for a redetermination. Use the deadline on that notice. See how to appeal a Medicare Advantage denial. Original Medicare uses a different path. See how to appeal an Original Medicare denial.
References: CMS: Medicare Part D exceptions, including step therapy · 42 CFR 423.578: Medicare Part D exceptions process · Medicare.gov: Filing an appeal
Can a Medicare Advantage plan use step therapy for a Part B drug?
Yes, within limits. 42 CFR 422.136 says that if a Medicare Advantage plan uses step therapy for Part B drugs, it must apply that step therapy only to new administrations, using a lookback of at least 365 days. It must not use, as a required step, a drug the plan does not cover as a Part B drug or, for an MA-PD plan, as a Part D drug. If you already received the drug during the lookback period, tell the plan and ask it to treat the request as a continuation rather than a new start. The plan's pharmacy and therapeutics committee reviews the step-therapy policy. You do not have to write to that committee yourself.
A request to skip the step is an organization determination. 42 CFR 422.568 says that for a Part B drug, the plan must notify you and the prescriber as expeditiously as your health requires, but no later than 72 hours after it receives the request, and that this 72-hour period may not be extended. 42 CFR 422.572 says that if the plan grants a request to expedite, it must decide a Part B drug request within 24 hours, and that this 24-hour period may not be extended. Ask the prescriber to request an expedited decision if waiting could seriously jeopardize your health. The denial notice explains how to appeal. Medicare.gov explains Medicare appeals, which are not the Marketplace external-review process. If the denial is for step therapy before intravenous immune globulin, see an IVIG denial.
References: 42 CFR 422.136: Medicare Advantage step therapy for Part B drugs · 42 CFR 422.568: Standard organization determination timeframes, including Part B drugs · 42 CFR 422.572: Timeframes for expedited Medicare Advantage organization determinations · Medicare.gov: Filing an appeal
What if my plan is not Medicare?
Use the process on the denial notice. For many job-based and individual plans, that is an internal appeal, and sometimes an external review after it. See how to appeal a health insurance denial and how to request an external review. Ask the prescriber for a statement that the required drug was tried and failed, or that it is likely to be ineffective or harmful, and attach the records that show that. If the required step is oral iron before an intravenous iron infusion, see an iron infusion denial. If the plan requires another diabetes drug before a GLP-1 prescribed for type 2 diabetes, see a diabetes medication denial.
45 CFR 156.122(c) is a different process. It applies to a health plan that provides essential health benefits, and it lets you, your designee, or your prescriber ask for a clinically appropriate drug the plan does not otherwise cover. The plan must decide a standard exception within 72 hours, and an expedited exception within 24 hours when exigent circumstances exist. The regulation says exigent circumstances exist when a health condition may seriously jeopardize your life, health, or ability to regain maximum function, or when you are in a current course of treatment with a non-formulary drug. If the plan grants the exception, it must treat the drug as an essential health benefit, including counting cost sharing toward the annual limit. If the plan denies the exception, you can ask an independent review organization to review that denial. 45 CFR 156.122(c)(3)(ii) says the plan must decide that external review, and send notice, no later than 72 hours after it receives a standard request, and no later than 24 hours after it receives an expedited request. Those hours are the time for the decision, not a deadline for you to file. A step-therapy denial of a drug the plan does cover, but only after another drug, may instead follow the appeal rules on the notice. Read the notice to see which process you were given.
Many states have statutes that limit step therapy for state-regulated insurance. Those laws differ, and this page does not list them. A self-funded employer plan is often outside a state insurance law even when an insurer administers the claims. Ask the plan whether your coverage is insured or self-funded, and ask your state insurance department whether a state step-therapy law applies. The National Association of Insurance Commissioners lists those departments. For mental health or substance use drugs, a step-therapy rule can also raise a parity question. See a denied mental health claim. If the denial is for step therapy for an ADHD medicine, see an ADHD medication denial.
References: 45 CFR 156.122: Essential health benefit prescription drug exceptions · HealthCare.gov: Internal appeals · HealthCare.gov: External review · NAIC: State insurance departments and how to file a complaint
What this page cannot promise
This is general information, not medical or legal advice. A plan can decide that the required drug is appropriate for you, that the supporting statement was incomplete, or that a state step-therapy law does not apply to your plan. A missed deadline on the notice can end that level of review. Nothing on this page promises that a plan, an independent reviewer, or Medicare will approve the drug.
Sources and further help
These sources provide general guidance. For a deadline or requirement that applies to you, follow your plan’s notice or the appropriate program’s current instructions.
- CMS: Medicare Part D exceptions, including step therapy ↗
- 42 CFR 423.578: Medicare Part D exceptions process ↗
- 42 CFR 422.136: Medicare Advantage step therapy for Part B drugs ↗
- 42 CFR 422.568: Standard organization determination timeframes, including Part B drugs ↗
- 42 CFR 422.572: Timeframes for expedited Medicare Advantage organization determinations ↗
- 45 CFR 156.122: Essential health benefit prescription drug exceptions ↗
- HealthCare.gov: Internal appeals ↗
- HealthCare.gov: External review ↗
- NAIC: State insurance departments and how to file a complaint ↗
- Medicare.gov: Filing an appeal ↗
Insurer websites may ask you to select your state or sign in. If a page will not open, use the member services number on your insurance card and ask for the current appeal instructions for your plan.